WCN26-5258 SUCCESSFUL HEMODIALYSIS INITIATION IN ACQUIRED HEMOPHILIA A MANAGED WITH SUSOCTOCOG ALFA AND EMICIZUMAB

Read full text Summarise with VIRAT
Authors: Ayano Kihara, Masanori Tamaki, Ryohei Sumitani, Chihiro Okinari, Miho Tada, Shinji Miyakami, Sumiyo Yamaguchi, Taizo Inagaki, Masanori Minato, Eriko Shibata, Kazuhiro Hasegawa, Shu Wakino
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Acquired hemophilia A (AHA) is a rare, life-threatening bleeding disorder caused by factor VIII inhibitors. In patients who require hemodialysis (HD), bleeding from vascular access and anticoagulation create unique hazards, making it difficult to safely initiate or maintain HD.

Fields of Study & Subjects

Hemophilia Treatment and Research Complement system in diseases Platelet Disorders and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105262–105262
Publication date
25 March 2026
Language
EN